{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:25:28Z","timestamp":1790785528208,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>AZD7442 is a combination of extended half-life, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\u2212specific neutralizing monoclonal antibodies (tixagevimab and cilgavimab).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study evaluated AZD7442 administered intramuscularly (300 mg) or intravenously (300, 1000, or 3000 mg) in healthy adults (aged 18\u201355 years). The primary end point was safety and tolerability. Secondary end points included pharmacokinetics and antidrug antibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between 18 August and 16 October 2020, a total of 60 participants were enrolled; 50 received AZD7442, and 10 received placebo. Adverse events (all of mild or moderate intensity) occurred in 26 participants (52.0%) in the AZD7442 groups and 8 (80.0%) in the placebo group. No infusion or injection site or hypersensitivity reactions occurred. Tixagevimab and cilgavimab had mean half-lives of approximately 90 days (range, 87.0\u201395.3 days for tixagevimab and 79.8\u2013\u00ad91.1 days for cilgavimab) and similar pharmacokinetic profiles over the 361-day study period. SARS-CoV-2\u2013specific neutralizing antibody titers provided by AZD7442 were maintained above those in plasma from convalescent patients with coronavirus disease 2019 (COVID-19).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>AZD7442 was well tolerated in healthy adults, showing a favorable safety profile across all doses. Depending on the SARS-CoV-2 variant, pharmacokinetic analyses suggest the AZD7442 could offer protection for \u22656 months against symptomatic COVID-19 after a single 300-mg intramuscular administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trials registration<\/jats:title>\n                  <jats:p>NCT04507256.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiad014","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T07:56:22Z","timestamp":1674460582000},"page":"1153-1163","source":"Crossref","is-referenced-by-count":32,"title":["Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults"],"prefix":"10.1093","volume":"227","author":[{"given":"Pablo","family":"Forte-Soto","sequence":"first","affiliation":[{"name":"Parexel Early Phase Clinical Unit , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Albayaty","sequence":"additional","affiliation":[{"name":"Parexel Early Phase Clinical Unit , London , United Kingdom"},{"name":"Patient Safety, Chief Medical Office, BioPharmaceuticals R&D, AstraZeneca , Cambridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Brooks","sequence":"additional","affiliation":[{"name":"Patient Safety, Chief Medical Office, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda H","family":"Arends","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tillinghast","sequence":"additional","affiliation":[{"name":"Data Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia A","family":"Aksyuk","sequence":"additional","affiliation":[{"name":"Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Bouquet","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca , South San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecil","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca , South San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asfiha","family":"Gebre","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Kubiak","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Pilla Reddy","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca , Cambridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Seegobin","sequence":"additional","affiliation":[{"name":"Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Cambridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Streicher","sequence":"additional","affiliation":[{"name":"Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Templeton","sequence":"additional","affiliation":[{"name":"Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Cambridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1689-3475","authenticated-orcid":false,"given":"Mark T","family":"Esser","sequence":"additional","affiliation":[{"name":"Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"2023051202560016400_jiad014-B1","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"2023051202560016400_jiad014-B2","doi-asserted-by":"crossref","first-page":"n1088","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"key":"2023051202560016400_jiad014-B3","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-021-01410-w","article-title":"Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom","volume":"27","author":"Pritchard","year":"2021","journal-title":"Nat Med"},{"key":"2023051202560016400_jiad014-B4","doi-asserted-by":"crossref","first-page":"n1943","DOI":"10.1136\/bmj.n1943","article-title":"Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: test negative design study","volume":"374","author":"Chung","year":"2021","journal-title":"BMJ"},{"key":"2023051202560016400_jiad014-B5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/vaccines9070708","article-title":"Serological response in lung transplant recipients after two doses of SARS-CoV-2 mRNA vaccines","volume":"9","author":"Narasimhan","year":"2021","journal-title":"Vaccines"},{"key":"2023051202560016400_jiad014-B6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(21)00460-6","article-title":"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study","volume":"22","author":"Antonelli","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023051202560016400_jiad014-B7","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"key":"2023051202560016400_jiad014-B8","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023051202560016400_jiad014-B9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med"},{"key":"2023051202560016400_jiad014-B10","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2021-324789","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"2023051202560016400_jiad014-B11","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"COVID-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"key":"2023051202560016400_jiad014-B12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab353","article-title":"Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era","volume":"8","author":"Agha","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023051202560016400_jiad014-B13","author":"National Institutes of Health"},{"key":"2023051202560016400_jiad014-B14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"2023051202560016400_jiad014-B15","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","article-title":"Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein","volume":"26","author":"Zost","year":"2020","journal-title":"Nat Med"},{"key":"2023051202560016400_jiad014-B16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci Transl Med"},{"key":"2023051202560016400_jiad014-B17","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41564-021-00972-2","article-title":"Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail","volume":"6","author":"Dong","year":"2021","journal-title":"Nat Microbiol"},{"key":"2023051202560016400_jiad014-B18","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023051202560016400_jiad014-B19","doi-asserted-by":"crossref","first-page":"e01714","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults","volume":"61","author":"Griffin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023051202560016400_jiad014-B20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2023051202560016400_jiad014-B21","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1107\/S0907444908007877","article-title":"Structural characterization of a human Fc fragment engineered for lack of effector functions","volume":"64","author":"Oganesyan","year":"2008","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"2023051202560016400_jiad014-B22","author":"US Food and Drug Administration"},{"key":"2023051202560016400_jiad014-B23","author":"Australian Government Department of Health"},{"key":"2023051202560016400_jiad014-B24","author":"Medicines and Healthcare Products Regulatory Agency"},{"key":"2023051202560016400_jiad014-B25","author":"European Medicines Agency"},{"key":"2023051202560016400_jiad014-B26","author":"AstraZeneca"},{"key":"2023051202560016400_jiad014-B27","author":"US Food and Drug Administration"},{"key":"2023051202560016400_jiad014-B28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"2023051202560016400_jiad014-B29","author":"US Food and Drug Administration"},{"key":"2023051202560016400_jiad014-B30","author":"US Food and Drug Administration"},{"key":"2023051202560016400_jiad014-B31","author":"Medicines and Healthcare Products Regulatory Agency"},{"key":"2023051202560016400_jiad014-B32","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"2023051202560016400_jiad014-B33","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2023051202560016400_jiad014-B34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"key":"2023051202560016400_jiad014-B35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"2023051202560016400_jiad014-B36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"2023051202560016400_jiad014-B37","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 omicron BA.4 and BA.5 from vaccine and BA.1 serum","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"},{"key":"2023051202560016400_jiad014-B38","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn8897","article-title":"Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529","volume":"376","author":"Zhou","year":"2022","journal-title":"Science"},{"key":"2023051202560016400_jiad014-B39","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave","volume":"22","author":"Al Jurdi","year":"2022","journal-title":"Am J Transplant"},{"key":"2023051202560016400_jiad014-B40","article-title":"Tixagevimab\/cilgavimab for prevention of COVID-19 during the omicron surge: retrospective analysis of national VA electronic data","author":"Young-Xu","journal-title":"medRxiv [Preprint: not peer reviewed]. 29 May 2022"},{"key":"2023051202560016400_jiad014-B41","author":"ClinicalTrials.gov"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad014\/49166344\/jiad014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/10\/1153\/50285516\/jiad014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/10\/1153\/50285516\/jiad014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T02:56:50Z","timestamp":1683860210000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/227\/10\/1153\/6997870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,1,23]]},"published-print":{"date-parts":[[2023,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad014","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,15]]},"published":{"date-parts":[[2023,1,23]]}}}